Prognostic merit of N-terminal-proBNP and N-terminal-proANP in mechanically ventilated critically ill patients

Acta Anaesthesiologica Scandinavica

Volumn 52, Issue 9, 2008, Pages 1265-1272

  Berdal, J E ^a   Stavem, K ^a   Omland, T ^a   Hall, C ^a   Smith Erichssen, N ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; VENOUS BLOOD;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CALIBRATION; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 51749095470     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2008.01737.x     Document Type: Article

References (37)

1. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003 362 : 316 22.
2. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, for the Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003 107 : 1278 83.
3. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002 89 : 463 5.
4. Omland T, Richards AM, Wergeland R, Vik-Mo H. B-Type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol 2005 95 : 24 8.
5. Maisel AS. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002 347 : 161 8.
6. Januzzi JL, Camargo CA, Anwaruddin S, Baggish A, Chen A, Krauser D, Tung R, Cameron R, Nagurney J, Chae C. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005 95 : 948 54.
7. Gegenhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 2006 52 : 827 31.
8. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel AS. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002 39 : 131 8.
9. Januzzi JL Jr., Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006 166 : 315 20.
10. Karmpaliotis D, Kirtane AJ, Ruisi CP, Polonsky T, Malhotra A, Talmor D, Kosmidou I, Jarolim P. de Lemos JA, Sabatine MS, Gibson CM, Morrow D. Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 2007 131 : 964 71.
11. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V, for the FINNSEPSIS Study Group. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007 35 : 1277 83.
12. Roch A, Allardet-Servent J, Michelet P, Oddoze C, Forel JM, Barrau K, Loundou A, Perrin G, Auffray JP, Portugal H, Papazian L. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005 33 : 1001 7.
13. Ueda S, Nishio K, Akai Y, Fukushima H, Ueyama T, Kawai Y, Masui K, Yoshioka A, Okuchi K. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock 2006 26 : 134 9.
14. Meyer B, Huelsmann M, Wexberg P, Karth GD, Berger R, Moertl D, Szekeres T, Pacher R, Heinz G. N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007 35 : 2268 73.
15. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005 9 : R37 45.
16. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, Dhainaut JF, Mira JP, Chiche JD. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004 32 : 660 5.
17. Berendes E, Van Aken H, Raufhake C, Schmidt C, Assmann G, Walter M. Differential secretion of atrial and brain natriuretic peptide in critically ill patients. Anesth Analg 2001 93 : 676 82.
18. Hoffmann U, Brueckmann M, Bertsch T, Wiessner M, Liebetrau C, Lang S, Haase KK, Borggrefe M, Huhle G. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin Lab 2005 51 : 373 9.
19. Mazul-Sunko B, Zarković N, Vrkić N, Antoljak N, Bekavac Beslin M, Nikolić Heitzler V, Siranović M, Krizmanić- Dekanić A, Klinger R. Pro-atrial natriuretic peptide hormone from right atria is correlated with cardiac depression in septic patients. J Endocrinol Investig 2001 24 : RC22 4.
20. McCabe WR, Jackson GG. Gram-negative bacteremia. 1. Etiology and ecology. Arch Intern Med 1962 110 : 847 55.
21. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993 270 : 2957 63.
22. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med 1996 22 : 707 10.
23. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988 66 (3) : 605 10.
24. Hosmer DW, Lemeshow S. Applied logistic regression. New York : John Wiley & Sons Inc., 1989.
25. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN, Val-HeFT Investigators. Direct comparison of the prognostic value of brain natriuretic peptide (BNP) and n-terminal proBNP in a large population of patients with chronic and symptomatic heart failure. The valsartan in heart failure (Val-HeFT) data. J Am Coll Cardiol 2006 47 : 71 2A.
26. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002 106 : 2913 8.
27. Januzzi JL, Morss A, Tung R, Pino R, Fifer MA, Thompson BT, Lee-Lewandrowski E. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care 2006 10 : R37.
28. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss C, Kaden JJ, Putensen C, Borggrefe M, Hoffmann U. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005 112 : 527 34.
29. Jefic D, Lee JW, Jefic D, Savoy-Moore RT, Rosman HS. Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 2005 128 : 288 95.
30. Elíasdóttir SB, Klemenzson G, Torfason B, Valsson F. Brain natriuretic peptide is a good predictor for outcome in cardiac surgery. Acta Anaesthesiol Scand 2008 52 : 182 7.
31. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocrine Rev 2003 24 : 341 56.
32. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004 36 : 505 13.
33. Almog Y, Novack V, Megralishvili R, Kobal S, Barski L, King D, Zahger D. Plasma level of N terminal pro-brain natriuretic peptide as a prognostic marker in critically ill patients. Anesth Analg 2006 102 : 1809 15.
34. Tomaru K, Arai M, Yokoyama T, Aihara Y, Sekiguchi K, Tanaka T, Nagai R, Kurabayashi M. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002 34 : 649 59.
35. He Q, LaPointe MC. Interleukin-1 beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999 33 : 283 9.
36. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005 46 : 610 20.
37. Mclean AS, Huang SJ, Nalos M, Tang B, Stewart DE. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma beta-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 2003 31 : 2611 8.